THERAPiN is focusing on creating a cutting edge unit of research and development of products based on active ingredients from the cannabis plant with the understanding that it has great potential both for the treatment of a variety of medical indications among patients and for improving the quality of life in general.
The company is investing in research and development in the field of medical cannabis and its products, through its senior and experienced staff in diverse fields that include:
THERAPiN will test the efficacy and safety of its products approved by the medical cannabis unit (IMCA), by conducting clinical research in collaboration with medical and academic institutions and professionals in Israel and around the world
Research and development of new formulas and products
In addition to products currently approved for marketing by the medical cannabis unit (IMCA), THERAPiN will develop other products, based on active ingredients from the cannabis plant, while creating collaborations with companies that develop products for the fields of medicine and patient welfare, in order to better address the variety of contraindications and medical conditions and while meeting the most stringent regulatory requirements.